Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells

Steffan T. Nawrocki, Jennifer S. Carew, Maria S. Pino, Ralph A. Highshaw, Robert H I Andtbacka, Kenneth Dunner, Ashutosh Pal, William G. Bornmann, Paul J. Chiao, Peng Huang, Henry Xiong, James L. Abbruzzese, David McConkey

Research output: Contribution to journalArticle

Abstract

The proteasome inhibitor bortezomib (formerly known as PS-341) recently received Food and Drug Administration approval for the treatment of multiple myeloma, and its activity is currently being evaluated in solid tumors. Bortezomib triggers apoptosis in pancreatic cancer cells, but the mechanisms involved have not been fully elucidated. Here, we show that pancreatic cancer cells exposed to bortezomib formed aggregates of ubiquitin-conjugated proteins ("aggresomes") in vitro and in vivo. Bortezomib-induced aggresome formation was determined to be cytoprotective and could be disrupted using histone deacetylase (HDAC) 6 small interfering RNA or chemical HDAC inhibitors, which resulted in endoplasmic reticulum stress and synergistic levels of apoptosis in vitro and in an orthotopic pancreatic cancer xenograft model in vivo. Interestingly, bortezomib did not induce aggresome formation in immortalized normal human pancreatic epithelial cells in vitro or in murine pancreatic epithelial cells in vivo. In addition, these cells did not undergo apoptosis following treatment with bortezomib, suberoylanilide hydroxamic acid, or the combination, showing tumor selectivity. Taken together, our study shows that inhibition of aggresome formation can strongly potentiate the efficacy of bortezomib and provides the foundation for clinical trials of bortezomib in combination with HDAC inhibitors for the treatment of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)3773-3781
Number of pages9
JournalCancer Research
Volume66
Issue number7
DOIs
StatePublished - Apr 1 2006
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Apoptosis
Histone Deacetylase Inhibitors
Epithelial Cells
Drug Approval
Bortezomib
Proteasome Inhibitors
Endoplasmic Reticulum Stress
Histone Deacetylases
United States Food and Drug Administration
Ubiquitin
Multiple Myeloma
Heterografts
Small Interfering RNA
Neoplasms
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Andtbacka, R. H. I., Dunner, K., ... McConkey, D. (2006). Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Research, 66(7), 3773-3781. https://doi.org/10.1158/0008-5472.CAN-05-2961

Aggresome disruption : A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. / Nawrocki, Steffan T.; Carew, Jennifer S.; Pino, Maria S.; Highshaw, Ralph A.; Andtbacka, Robert H I; Dunner, Kenneth; Pal, Ashutosh; Bornmann, William G.; Chiao, Paul J.; Huang, Peng; Xiong, Henry; Abbruzzese, James L.; McConkey, David.

In: Cancer Research, Vol. 66, No. 7, 01.04.2006, p. 3773-3781.

Research output: Contribution to journalArticle

Nawrocki, ST, Carew, JS, Pino, MS, Highshaw, RA, Andtbacka, RHI, Dunner, K, Pal, A, Bornmann, WG, Chiao, PJ, Huang, P, Xiong, H, Abbruzzese, JL & McConkey, D 2006, 'Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells', Cancer Research, vol. 66, no. 7, pp. 3773-3781. https://doi.org/10.1158/0008-5472.CAN-05-2961
Nawrocki, Steffan T. ; Carew, Jennifer S. ; Pino, Maria S. ; Highshaw, Ralph A. ; Andtbacka, Robert H I ; Dunner, Kenneth ; Pal, Ashutosh ; Bornmann, William G. ; Chiao, Paul J. ; Huang, Peng ; Xiong, Henry ; Abbruzzese, James L. ; McConkey, David. / Aggresome disruption : A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. In: Cancer Research. 2006 ; Vol. 66, No. 7. pp. 3773-3781.
@article{01ef96af92b641da898358c846253ad6,
title = "Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells",
abstract = "The proteasome inhibitor bortezomib (formerly known as PS-341) recently received Food and Drug Administration approval for the treatment of multiple myeloma, and its activity is currently being evaluated in solid tumors. Bortezomib triggers apoptosis in pancreatic cancer cells, but the mechanisms involved have not been fully elucidated. Here, we show that pancreatic cancer cells exposed to bortezomib formed aggregates of ubiquitin-conjugated proteins ({"}aggresomes{"}) in vitro and in vivo. Bortezomib-induced aggresome formation was determined to be cytoprotective and could be disrupted using histone deacetylase (HDAC) 6 small interfering RNA or chemical HDAC inhibitors, which resulted in endoplasmic reticulum stress and synergistic levels of apoptosis in vitro and in an orthotopic pancreatic cancer xenograft model in vivo. Interestingly, bortezomib did not induce aggresome formation in immortalized normal human pancreatic epithelial cells in vitro or in murine pancreatic epithelial cells in vivo. In addition, these cells did not undergo apoptosis following treatment with bortezomib, suberoylanilide hydroxamic acid, or the combination, showing tumor selectivity. Taken together, our study shows that inhibition of aggresome formation can strongly potentiate the efficacy of bortezomib and provides the foundation for clinical trials of bortezomib in combination with HDAC inhibitors for the treatment of pancreatic cancer.",
author = "Nawrocki, {Steffan T.} and Carew, {Jennifer S.} and Pino, {Maria S.} and Highshaw, {Ralph A.} and Andtbacka, {Robert H I} and Kenneth Dunner and Ashutosh Pal and Bornmann, {William G.} and Chiao, {Paul J.} and Peng Huang and Henry Xiong and Abbruzzese, {James L.} and David McConkey",
year = "2006",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-05-2961",
language = "English (US)",
volume = "66",
pages = "3773--3781",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Aggresome disruption

T2 - A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells

AU - Nawrocki, Steffan T.

AU - Carew, Jennifer S.

AU - Pino, Maria S.

AU - Highshaw, Ralph A.

AU - Andtbacka, Robert H I

AU - Dunner, Kenneth

AU - Pal, Ashutosh

AU - Bornmann, William G.

AU - Chiao, Paul J.

AU - Huang, Peng

AU - Xiong, Henry

AU - Abbruzzese, James L.

AU - McConkey, David

PY - 2006/4/1

Y1 - 2006/4/1

N2 - The proteasome inhibitor bortezomib (formerly known as PS-341) recently received Food and Drug Administration approval for the treatment of multiple myeloma, and its activity is currently being evaluated in solid tumors. Bortezomib triggers apoptosis in pancreatic cancer cells, but the mechanisms involved have not been fully elucidated. Here, we show that pancreatic cancer cells exposed to bortezomib formed aggregates of ubiquitin-conjugated proteins ("aggresomes") in vitro and in vivo. Bortezomib-induced aggresome formation was determined to be cytoprotective and could be disrupted using histone deacetylase (HDAC) 6 small interfering RNA or chemical HDAC inhibitors, which resulted in endoplasmic reticulum stress and synergistic levels of apoptosis in vitro and in an orthotopic pancreatic cancer xenograft model in vivo. Interestingly, bortezomib did not induce aggresome formation in immortalized normal human pancreatic epithelial cells in vitro or in murine pancreatic epithelial cells in vivo. In addition, these cells did not undergo apoptosis following treatment with bortezomib, suberoylanilide hydroxamic acid, or the combination, showing tumor selectivity. Taken together, our study shows that inhibition of aggresome formation can strongly potentiate the efficacy of bortezomib and provides the foundation for clinical trials of bortezomib in combination with HDAC inhibitors for the treatment of pancreatic cancer.

AB - The proteasome inhibitor bortezomib (formerly known as PS-341) recently received Food and Drug Administration approval for the treatment of multiple myeloma, and its activity is currently being evaluated in solid tumors. Bortezomib triggers apoptosis in pancreatic cancer cells, but the mechanisms involved have not been fully elucidated. Here, we show that pancreatic cancer cells exposed to bortezomib formed aggregates of ubiquitin-conjugated proteins ("aggresomes") in vitro and in vivo. Bortezomib-induced aggresome formation was determined to be cytoprotective and could be disrupted using histone deacetylase (HDAC) 6 small interfering RNA or chemical HDAC inhibitors, which resulted in endoplasmic reticulum stress and synergistic levels of apoptosis in vitro and in an orthotopic pancreatic cancer xenograft model in vivo. Interestingly, bortezomib did not induce aggresome formation in immortalized normal human pancreatic epithelial cells in vitro or in murine pancreatic epithelial cells in vivo. In addition, these cells did not undergo apoptosis following treatment with bortezomib, suberoylanilide hydroxamic acid, or the combination, showing tumor selectivity. Taken together, our study shows that inhibition of aggresome formation can strongly potentiate the efficacy of bortezomib and provides the foundation for clinical trials of bortezomib in combination with HDAC inhibitors for the treatment of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=33645737411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645737411&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-2961

DO - 10.1158/0008-5472.CAN-05-2961

M3 - Article

C2 - 16585204

AN - SCOPUS:33645737411

VL - 66

SP - 3773

EP - 3781

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -